Tag: FDA

Politics Is Costing Lives by Delaying Right-to-Try Legislation »

Upon deeper inspection, it seems the conventional arguments against right-to-try come up short.

Misdiagnosing Right-to-try Laws »

Right-to-try laws only apply to terminally ill patients who have exhausted all other options.

Medical Apps: Improving Healthcare on a Global Scale »

Health apps use smartphone technology to provide medical assistance or access to medical professionals.

Want a Happier, Healthier, and More Prosperous Society? Try Freedom, Innovation and Incentives »

“I will promote freedom at all costs,” is the first line of the Draper University pledge. Draper University of Heroes is a school I created to encourage people with ideas and energy to pursue their visions through entrepreneurship and risktaking. For an entrepreneur, freedom matters most. The ability to try new things without government...
Read More »

American Patients Can Access Far More New Cancer Drugs than Others Can »

New research by scholars at the University of Pittsburgh shows that American patients have significantly better access to new cancer medicines than their peers in other developed countries: Of 45 anticancer drug indications approved in the United States between January 1, 2009, and December 31, 2013, 64% (29) were approved by the European Medicines...
Read More »

The FDA Cannot Hire Staff with Starting Salaries of $160,000 »

Would a starting salary of just above $160,000 turn you off? Well, maybe if you had a scientific PhD and had to wait four months before the employer could decide whether to hire you or not, you would find a spot elsewhere. This is the situation the Food and Drug Administration finds itself in,...
Read More »

Good and Bad News on Generic Drug Approvals »

A solution to expensive patented medicines is generic competitors. The United States has struck a pretty good balance between innovation and low prices through the Hatch-Waxman (1984) Act, which specified patent terms for newly invented medicines, and a pathway for generic competitors to enter the market after a period. One obstacle to generic entry...
Read More »

One Solution to the EpiPen Crisis: Repeal Durham-Humphrey! »

Posturing politicians on Capitol Hill conducted a hearing a few days ago during which they grilled Heather Bresch, CEO of Mylan N.V., maker of EpiPens. Prices of EpiPens have skyrocketed in the past few years (which I have discussed here and here). The politicians were more interested in wagging their fingers and tut-tutting at...
Read More »

Trumped on Health Care! »

Donald Trump does not want Chinese goods or Mexican workers to come into America. However, there appears to be one set of items he wants to cross our border, according to his Healthcare Plan to Make America Great Again: Remove barriers to entry into free markets for drug providers that offer safe, reliable and...
Read More »

Ten Percent of Cancer Drug Spending Is Wasted »

A remarkable study published in the BMJ concludes that $1.8 billion of the $18 billion spent on the 20 most expensive cancer drugs in the United States is wasted due to cunning marketing by drug-makers. Chemotherapeutic doses are often adjusted by body weight. However, the drugs are shipped in vials containing doses appropriate to...
Read More »

  • MyGovCost.org
  • FDAReview.org
  • OnPower.org
  • elindependent.org